Medtronic plc (MDT) Bundle
A Brief History of Medtronic plc (MDT)
Company Overview
Medtronic plc is a global medical technology company headquartered in Dublin, Ireland. As of 2024, the company operates in over 160 countries with annual revenue of $31.7 billion for fiscal year 2023.
Financial Performance
| Fiscal Year | Revenue | Net Income | Market Capitalization |
|---|---|---|---|
| 2023 | $31.7 billion | $5.2 billion | $107.3 billion |
Key Business Segments
- Cardiovascular
- Medical Surgical
- Neuroscience
- Diabetes
Operational Statistics
As of 2024, Medtronic employs approximately 95,000 people worldwide and maintains 400+ manufacturing facilities globally.
Research and Development
Medtronic invested $2.6 billion in R&D during fiscal year 2023, representing 8.2% of total revenue.
Global Presence
| Region | Revenue Contribution |
|---|---|
| United States | 65% |
| International Markets | 35% |
Stock Performance
MDT stock price as of January 2024: $85.43 per share. Dividend yield: 3.1%
A Who Owns Medtronic plc (MDT)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| The Vanguard Group, Inc. | 143,989,401 | 10.24% |
| BlackRock Inc. | 129,328,804 | 9.21% |
| State Street Corporation | 81,298,820 | 5.79% |
| Capital World Investors | 72,126,404 | 5.14% |
Top Individual Shareholders
- Omar Ishrak (Former Chairman and CEO): 270,192 shares
- Geoff Martha (Current Chairman and CEO): 198,456 shares
Ownership Structure
Public Float: 94.86%
Institutional Ownership: 80.12%
Mutual Fund Ownership
| Fund Name | Shares Owned |
|---|---|
| Vanguard Total Stock Market Index Fund | 37,456,789 |
| Vanguard 500 Index Fund | 28,765,432 |
| Fidelity Contrafund | 22,345,678 |
Geographical Ownership Distribution
- United States: 85.67%
- International Investors: 14.33%
Medtronic plc (MDT) Mission Statement
Core Mission Statement
Medtronic's mission statement focuses on alleviating pain, restoring health, and extending life for patients worldwide through medical technology innovation.
Financial Performance Metrics
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $31.7 billion |
| Net Income | $4.8 billion |
| Research & Development Spending | $2.6 billion |
| Global Employee Count | 95,000 |
Strategic Focus Areas
- Cardiac and Vascular Technologies
- Diabetes Management Solutions
- Neurological Interventions
- Surgical Technologies
- Patient Monitoring Systems
Key Innovation Metrics
| Innovation Indicator | 2023 Data |
|---|---|
| Active Patents | 7,500+ |
| New Product Launches | 35 |
| Clinical Trials Ongoing | 250+ |
Global Market Presence
Geographic Revenue Distribution:
- United States: 64%
- Europe: 18%
- Asia Pacific: 12%
- Other Regions: 6%
Product Portfolio Breakdown
| Medical Segment | Revenue Contribution |
|---|---|
| Cardiac and Vascular | $11.2 billion |
| Diabetes | $3.5 billion |
| Neuroscience | $6.8 billion |
| Surgical Technologies | $7.4 billion |
| Patient Monitoring | $2.8 billion |
How Medtronic plc (MDT) Works
Company Overview
Medtronic plc is a global medical technology company headquartered in Dublin, Ireland. As of fiscal year 2023, the company reported total revenue of $31.7 billion.
Business Segments
| Cardiovascular Segment | $11.2 billion revenue |
| Diabetes Operating Unit | $3.1 billion revenue |
| Medical Surgical Portfolio | $8.9 billion revenue |
| Neuroscience Portfolio | $8.5 billion revenue |
Global Presence
Medtronic operates in over 150 countries with approximately 90,000 employees worldwide.
Research and Development
R&D investment in fiscal year 2023: $2.6 billion
Product Portfolio
- Cardiac Devices
- Insulin Pumps
- Surgical Technologies
- Neurological Devices
- Patient Monitoring Systems
Financial Performance
| Market Capitalization | $116.4 billion |
| Net Income 2023 | $5.2 billion |
| Gross Margin | 67.3% |
Key Operational Metrics
- Annual Patent Filings: 1,600
- Global Manufacturing Facilities: 50
- Research Centers: 22
How Medtronic plc (MDT) Makes Money
Revenue Breakdown by Business Segment
| Business Segment | Annual Revenue (2023) | Percentage of Total Revenue |
|---|---|---|
| Cardiovascular | $11.2 billion | 31.4% |
| Medical Surgical | $9.8 billion | 27.5% |
| Neuroscience | $8.6 billion | 24.2% |
| Diabetes | $3.9 billion | 11.0% |
| Total Revenue | $35.5 billion | 100% |
Product Categories
- Cardiac Devices: Pacemakers, Defibrillators
- Surgical Technologies: Minimally Invasive Surgical Tools
- Neurostimulation Devices
- Insulin Pumps and Continuous Glucose Monitoring Systems
Geographic Revenue Distribution
| Region | Revenue | Percentage |
|---|---|---|
| United States | $22.1 billion | 62.3% |
| International Markets | $13.4 billion | 37.7% |
Research and Development Investment
R&D Spending in 2023: $2.4 billion, representing 6.8% of total revenue
Profit Metrics
Net Income 2023: $5.7 billion
Gross Margin: 67.3%
Operating Margin: 24.6%
Key Revenue Drivers
- Innovative Medical Technologies
- Global Healthcare Market Expansion
- Strategic Acquisitions
- Strong Patent Portfolio
Medtronic plc (MDT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.